{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fher2-targeted-adcs-clinical-data-GObe0J_L","width":444,"version":"1.0","type":"rich","title":"Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/8fe25f2f-dd82-4745-8a5d-6e4e5929ba32/100524-multitumor-her2-am-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/90189450-740b-4578-9b7e-f8f089feb3c6\" height=\"200\" width=\"100%\" title=\"Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"This podcast explores the evolving role of HER2-targeted antibody–drug conjugates, exploring their mechanisms of action, and emerging clinical data across genitourinary, gastrointestinal, and gynecologic cancers."}